This phase I/II trial is evaluating a new type of immunotherapy, known as a neoantigen cancer vaccine, in combination with two established immunotherapies, as a treatment for several different types of cancer.
This trial is treating patients with non-small cell lung cancer, colorectal cancer, gastro-oesophageal cancer or urothelial cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors
Commercial Sponsor
Gritstone Oncology, Bristol-Myers Squibb (BMS)
Recruiting Hospitals Read More